Stocktoria
VERU INC. VERU
VERU INC. (VERU) earns a Piotroski F-score of 0/9 (weak financial health). It pays a dividend yielding 0.01% (safety: no dividend).
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.67 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 0/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VERU | VERU INC. | 0/9 | — | — | +3.6% |
| JNJ | JOHNSON & JOHNSON | 4/9 | — | 22.9 | +6% |
| LLY | ELI LILLY & Co | 7/9 | — | 55.1 | +44.7% |
| MRK | Merck & Co., Inc. | 4/9 | — | 17.4 | +1.3% |
| PFE | PFIZER INC | 4/9 | — | 17.8 | -1.6% |
| ABBV | AbbVie Inc. | 7/9 | -0.34 | 105.9 | +8.6% |
| BMY | BRISTOL MYERS SQUIBB CO | 7/9 | — | 16.7 | -0.2% |
About VERU INC.
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
FAQ
Is VERU financially healthy?
VERU INC.'s Piotroski F-score is 0/9 (8–9 is excellent, 0–3 weak).
Does VERU pay a dividend, and is it safe?
Yes. VERU INC. pays a dividend yielding about 0.01% with a None payout ratio, rated “no dividend” for safety.
How profitable is VERU?
In FY2025, VERU INC. had a return on equity of -124.0%.
Is VERU overvalued or undervalued?
VERU INC. trades at about 30.4× trailing earnings — below its 10-year norm (10-year range 114.0×–950.0×, median 239.5×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for VERU?
The average Wall-Street price target for VERU INC. is $24.50, about 794.2% above the recent price, from 2 analysts.
Is VERU a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on VERU INC.: a Piotroski F-score of 0/9, a dividend yield of 0.01%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.